These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35142024)

  • 1. Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race.
    Babulal GM; Franzen S; Abner EL; Smith JE; van den Berg E; Mindt MR; van Bruchem-Visser RL; Schneider LS; Prins ND; Papma JM
    Alzheimers Dement; 2022 Apr; 18(4):867-868. PubMed ID: 35142024
    [No Abstract]   [Full Text] [Related]  

  • 2. Reporting and social construction of race in Alzheimer's disease clinical trials.
    Hu WT
    Alzheimers Dement; 2022 Apr; 18(4):865-866. PubMed ID: 35142032
    [No Abstract]   [Full Text] [Related]  

  • 3. Demographic Analysis of Industry-Sponsored Alzheimer's Disease Trial Populations in the United States.
    Peroutka SJ
    J Prev Alzheimers Dis; 2023; 10(1):130-132. PubMed ID: 36641617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global issues in drug development for Alzheimer's disease.
    Doody RS; Cole PE; Miller DS; Siemers E; Black R; Feldman H; Schindler R; Graham S; Heath T; Khachaturian AS; Evans R; Carrillo MC
    Alzheimers Dement; 2011 Mar; 7(2):197-207. PubMed ID: 21414556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of Alzheimer's disease: consequence for drug trials?
    Devi G; Scheltens P
    Alzheimers Res Ther; 2018 Dec; 10(1):122. PubMed ID: 30567585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review.
    Canevelli M; Bruno G; Grande G; Quarata F; Raganato R; Remiddi F; Valletta M; Zaccaria V; Vanacore N; Cesari M
    Neurosci Biobehav Rev; 2019 Jun; 101():122-128. PubMed ID: 30946856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
    Cully M
    Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
    [No Abstract]   [Full Text] [Related]  

  • 9. Alzheimer's drug trials plagued by lack of racial diversity.
    Reardon S
    Nature; 2023 Aug; 620(7973):256-257. PubMed ID: 37532857
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug development status for Alzheimer's disease: present scenario.
    Misra S; Medhi B
    Neurol Sci; 2013 Jun; 34(6):831-9. PubMed ID: 23392897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.
    Raman R; Aisen PS; Carillo MC; Detke M; Grill JD; Okonkwo OC; Rivera-Mindt M; Sabbagh M; Vellas B; Weiner M; Sperling R
    J Prev Alzheimers Dis; 2022; 9(3):388-392. PubMed ID: 35841239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment.
    Schneider LS
    Alzheimer Dis Assoc Disord; 2005; 19(4):279-83. PubMed ID: 16327360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On weighted composite scores for early Alzheimer's trials.
    Jin K; Cameron B; Dunn B
    Pharm Stat; 2019 Mar; 18(2):239-247. PubMed ID: 30565432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta JM; Birks J
    Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
    DeBattista C; Belanoff J
    Curr Alzheimer Res; 2005 Apr; 2(2):125-9. PubMed ID: 15974908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease biomarkers: their value in diagnosis and clinical trials.
    Small DH
    Front Biosci; 2002 Apr; 7():d986-8. PubMed ID: 11897567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective pharmacologic management of Alzheimer's disease.
    Farlow MR; Cummings JL
    Am J Med; 2007 May; 120(5):388-97. PubMed ID: 17466645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building a roadmap for developing combination therapies for Alzheimer's disease.
    Perry D; Sperling R; Katz R; Berry D; Dilts D; Hanna D; Salloway S; Trojanowski JQ; Bountra C; Krams M; Luthman J; Potkin S; Gribkoff V; Temple R; Wang Y; Carrillo MC; Stephenson D; Snyder H; Liu E; Ware T; McKew J; Fields FO; Bain LJ; Bens C
    Expert Rev Neurother; 2015 Mar; 15(3):327-33. PubMed ID: 25708309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.